5/07/2013
On Background checks...
Increasing background checks is a covert means of denying the franchise a priori, at this point it can not be separated from the radical political agenda that seeks total civilian disarmament which is today the LEADERSHIP of the anti-gun potemkin villages (MAIG, etc). It can not be separated because the means by which this system of expanded background checks is said to be enacted is from the top down, at the "Federal" level, made in the sausage factory of beltway insiders and New York money lenders to close the "iron collars" around the great toiling masses of little people. More reason? It sounds to me like more paternalism, less state's rights, the agenda leading us towards one big dull grey North American Union.
Subscribe to:
Post Comments (Atom)
The anti-cancer drug regorafenib the treatment of gastrointestinal stromal tumors
ReplyDeleteGastrointestinal stromal tumor originated in the gastrointestinal mesenchymal tissue tumors, accounting for the majority of gastrointestinal mesenchymal tumors.
Gastrointestinal stromal tumors account for 1-3% of gastrointestinal cancers, with an estimated annual incidence of approximately 10-20/100 000, occurs mainly in middle-aged patients, rare in patients under 40 years of age, no significant difference in the incidence of men and women.
Recently, the U.S. Department of Health regulatory approval granted to Bayer's anti-cancer drug the regorafenib qualifications for the treatment of gastrointestinal stromal tumor priority review, which will speed up the pace of the treatment listed.
For some drugs than existing treatments bring significant therapeutic progress, the U.S. Food and Drug Administration priority review. This review only takes six months, instead of the usual 10-12 months.
Regorafenib (trade name Stivarga) is a novel multi-kinase inhibitor that can block a variety of enzymes to promote tumor growth, on September 27 this year, approved by the FDA for the treatment of metastatic colorectal cancer.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
TG 100572
Bosutinib
Nilotinib
Dasatinib
Saracatinib
Fingolimod
Bafetinib
R406 free base
R406
R788(prodrug of R406)